A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引：5
|
作者：
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
机构：
[1] Acibadem Univ, Adana, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Baskent Univ, Radiat Oncol, Adana, Turkey
[4] Marmara Univ, Istanbul, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Ankara, Turkey
[7] Baskent Univ, Adana, Turkey
[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey
[9] Gaziantep Univ, Gaziantep, Turkey
[10] Ege Univ, Izmir, Turkey
[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey
[12] Roche Pharmaceut, Istanbul, Turkey
[13] Medstats Consulting, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS182
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER
    Polanco, C.
    Carulla, M.
    Badia, X.
    Ramirez-Arellano, A.
    VALUE IN HEALTH, 2008, 11 (06) : A468 - A468
  • [32] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Akira Sawaki
    Yasuo Ohashi
    Yasushi Omuro
    Taroh Satoh
    Yasuo Hamamoto
    Narikazu Boku
    Yoshinori Miyata
    Hiroya Takiuchi
    Kensei Yamaguchi
    Yasutsuna Sasaki
    Tomohiro Nishina
    Atsushi Satoh
    Eishi Baba
    Takao Tamura
    Takashi Abe
    Kiyohiko Hatake
    Atsushi Ohtsu
    Gastric Cancer, 2012, 15 : 313 - 322
  • [33] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Sawaki, Akira
    Ohashi, Yasuo
    Omuro, Yasushi
    Satoh, Taroh
    Hamamoto, Yasuo
    Boku, Narikazu
    Miyata, Yoshinori
    Takiuchi, Hiroya
    Yamaguchi, Kensei
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Satoh, Atsushi
    Baba, Eishi
    Tamura, Takao
    Abe, Takashi
    Hatake, Kiyohiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2012, 15 (03) : 313 - 322
  • [34] Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer (vol 51, pg 482, 2015)
    Ryu, Min-Hee
    Yoo, Changhoon
    Kim, Jong Gwang
    Ryoo, Baek-Yeol
    Park, Young Soo
    Park, Sook Ryun
    Han, Hye-Suk
    Chung, Ik Joo
    Song, Eun-Kee
    Lee, Kyung Hee
    Kang, Seok Yun
    Kang, Yoon-Koo
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 187 - 187
  • [35] Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
    Satoh, Taroh
    Omuro, Yasushi
    Sasaki, Yasutsuna
    Hamamoto, Yasuo
    Boku, Narikazu
    Tamura, Takao
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 949 - 955
  • [36] Phase I/II study of genasense (G3139) in combination with cisplatin (Cis) and fluorouracil (FU) in patients with advanced esophageal, gastro-esophageal junction and gastric cancer (P5385).
    Kaubisch, A
    Wu, YH
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 884S - 884S
  • [37] Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
    Taroh Satoh
    Yasushi Omuro
    Yasutsuna Sasaki
    Yasuo Hamamoto
    Narikazu Boku
    Takao Tamura
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 949 - 955
  • [38] Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
    Verhoeven, R. H. A.
    Kuijper, S.
    Lordick, F.
    Slingerland, M.
    Qin, A.
    van Laarhoven, H. W. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S878 - S878
  • [39] Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study
    Vermeulen, Bram D.
    Bruggeman, Lukas
    Bac, Dirk J.
    Schrauwen, Ruud W. M.
    Epping, Ludger S. M.
    Scheffer, Robert C. H.
    Tan, Adriaan C. I. T. L.
    Groenen, Marcel J. M.
    Verhoeven, Rob H. A.
    Siersema, Peter D.
    ACTA ONCOLOGICA, 2020, 59 (04) : 410 - 416
  • [40] Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study
    Longo, F.
    Jorge Fernandez, M.
    Yaya Tur, R.
    Fernandez Montes, A.
    Martinez Lago, N.
    Brozos Vazquez, E.
    Aparicio Urtasun, J.
    Quintero Aldana, G.
    Ceballos Barbancho, E.
    Buxo Orra, E.
    Lopez Munoz, A.
    Pellon Augusto, M.
    Molina Villaverde, R.
    Diaz-Paniagua, L.
    Cerda Serda, P.
    Lopez-Leiva, P.
    Martin-Carnicero, A.
    Cousillas Castineiras, A.
    Paris Bouzas, L.
    Garcia Paredes, B.
    Romero Reinoso, C.
    Ortega Sedano, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S103 - S103
12345